| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 20 | 2023 | 95 | 7.280 |
Why?
|
| Arthroplasty, Replacement, Hip | 15 | 2022 | 56 | 5.070 |
Why?
|
| Osteoarthritis, Knee | 13 | 2023 | 199 | 3.700 |
Why?
|
| Osteoarthritis, Hip | 7 | 2022 | 18 | 2.310 |
Why?
|
| Arthroplasty, Replacement | 5 | 2014 | 13 | 2.260 |
Why?
|
| Hip Prosthesis | 12 | 2018 | 20 | 2.240 |
Why?
|
| Registries | 8 | 2015 | 664 | 1.710 |
Why?
|
| Arthralgia | 4 | 2015 | 49 | 1.690 |
Why?
|
| Orthopedic Procedures | 5 | 2019 | 34 | 1.650 |
Why?
|
| Orthopedics | 6 | 2019 | 22 | 1.550 |
Why?
|
| Treatment Outcome | 27 | 2023 | 3952 | 1.510 |
Why?
|
| Knee Joint | 9 | 2023 | 167 | 1.480 |
Why?
|
| Prosthesis Failure | 13 | 2015 | 49 | 1.420 |
Why?
|
| Pain Measurement | 8 | 2017 | 264 | 1.410 |
Why?
|
| Bone Cements | 8 | 2004 | 14 | 1.350 |
Why?
|
| Disability Evaluation | 5 | 2015 | 181 | 1.260 |
Why?
|
| Patient Outcome Assessment | 3 | 2017 | 45 | 1.240 |
Why?
|
| Patient Satisfaction | 7 | 2023 | 367 | 1.190 |
Why?
|
| Quality Indicators, Health Care | 3 | 2013 | 319 | 1.160 |
Why?
|
| Titanium | 7 | 2019 | 51 | 1.060 |
Why?
|
| Patient Selection | 3 | 2015 | 352 | 1.010 |
Why?
|
| Osteoarthritis | 4 | 2021 | 57 | 0.890 |
Why?
|
| Humans | 68 | 2023 | 50636 | 0.890 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 10 | 0.820 |
Why?
|
| Polyethylene | 4 | 2018 | 10 | 0.810 |
Why?
|
| Retinal Detachment | 1 | 2021 | 16 | 0.810 |
Why?
|
| Quality of Life | 4 | 2023 | 782 | 0.810 |
Why?
|
| Talus | 1 | 2020 | 1 | 0.810 |
Why?
|
| Osteonecrosis | 1 | 2020 | 4 | 0.800 |
Why?
|
| Polyethylenes | 3 | 2015 | 6 | 0.790 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 44 | 0.770 |
Why?
|
| Recovery of Function | 5 | 2023 | 196 | 0.770 |
Why?
|
| Aged | 26 | 2023 | 10999 | 0.770 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 688 | 0.690 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 11 | 0.690 |
Why?
|
| Tantalum | 2 | 2015 | 4 | 0.690 |
Why?
|
| Metal-on-Metal Joint Prostheses | 1 | 2018 | 1 | 0.680 |
Why?
|
| Perioperative Care | 2 | 2018 | 58 | 0.680 |
Why?
|
| Critical Pathways | 1 | 2018 | 21 | 0.670 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 32 | 0.670 |
Why?
|
| Bone Morphogenetic Protein 2 | 8 | 2017 | 44 | 0.660 |
Why?
|
| Hip Fractures | 1 | 2018 | 69 | 0.640 |
Why?
|
| Femur | 5 | 2014 | 40 | 0.630 |
Why?
|
| Prospective Studies | 9 | 2023 | 2591 | 0.620 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2023 | 77 | 0.600 |
Why?
|
| Radiostereometric Analysis | 2 | 2015 | 2 | 0.580 |
Why?
|
| Biocompatible Materials | 6 | 2019 | 135 | 0.580 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2293 | 0.570 |
Why?
|
| Patient Care Team | 1 | 2018 | 280 | 0.560 |
Why?
|
| Risk Adjustment | 2 | 2017 | 72 | 0.560 |
Why?
|
| Knee Prosthesis | 4 | 2001 | 5 | 0.550 |
Why?
|
| Vancomycin | 4 | 2023 | 21 | 0.540 |
Why?
|
| Middle Aged | 22 | 2022 | 13532 | 0.530 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 31 | 0.530 |
Why?
|
| Musculoskeletal Diseases | 1 | 2015 | 83 | 0.530 |
Why?
|
| Coated Materials, Biocompatible | 4 | 2019 | 39 | 0.520 |
Why?
|
| Femoral Fractures | 6 | 2015 | 21 | 0.510 |
Why?
|
| Workload | 1 | 2015 | 113 | 0.500 |
Why?
|
| Osteogenesis | 10 | 2019 | 137 | 0.490 |
Why?
|
| Quality Improvement | 2 | 2018 | 362 | 0.480 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 233 | 0.480 |
Why?
|
| Models, Psychological | 1 | 2013 | 94 | 0.480 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 152 | 0.470 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 683 | 0.470 |
Why?
|
| Postoperative Care | 3 | 2010 | 92 | 0.470 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 34 | 0.450 |
Why?
|
| Information Dissemination | 1 | 2013 | 109 | 0.450 |
Why?
|
| Surgeons | 1 | 2015 | 132 | 0.450 |
Why?
|
| Low Back Pain | 1 | 2013 | 108 | 0.440 |
Why?
|
| Bone Substitutes | 4 | 2014 | 15 | 0.440 |
Why?
|
| Chondrocytes | 4 | 2016 | 39 | 0.440 |
Why?
|
| Tibia | 3 | 2020 | 52 | 0.430 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 106 | 0.430 |
Why?
|
| Schools, Medical | 1 | 2012 | 135 | 0.420 |
Why?
|
| Cartilage, Articular | 3 | 2017 | 43 | 0.420 |
Why?
|
| Emotions | 1 | 2013 | 196 | 0.410 |
Why?
|
| Femur Head | 2 | 2009 | 3 | 0.410 |
Why?
|
| Male | 29 | 2021 | 23332 | 0.410 |
Why?
|
| Patient Readmission | 1 | 2015 | 357 | 0.400 |
Why?
|
| Range of Motion, Articular | 2 | 2008 | 73 | 0.400 |
Why?
|
| Osteolysis | 4 | 2010 | 17 | 0.400 |
Why?
|
| Mental Health | 1 | 2013 | 293 | 0.400 |
Why?
|
| Postoperative Complications | 7 | 2018 | 883 | 0.390 |
Why?
|
| Staphylococcal Infections | 2 | 2023 | 97 | 0.390 |
Why?
|
| Bone and Bones | 4 | 2015 | 146 | 0.380 |
Why?
|
| Narcotics | 1 | 2010 | 47 | 0.380 |
Why?
|
| Cementation | 3 | 2004 | 3 | 0.380 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 363 | 0.370 |
Why?
|
| Pain, Postoperative | 3 | 2023 | 102 | 0.370 |
Why?
|
| Tissue Scaffolds | 4 | 2019 | 75 | 0.370 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 227 | 0.370 |
Why?
|
| Preoperative Care | 1 | 2010 | 143 | 0.360 |
Why?
|
| Walking | 2 | 2008 | 205 | 0.360 |
Why?
|
| United States | 8 | 2017 | 6433 | 0.360 |
Why?
|
| Female | 25 | 2020 | 26612 | 0.350 |
Why?
|
| Activities of Daily Living | 3 | 2023 | 272 | 0.350 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 369 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 590 | 0.340 |
Why?
|
| Prosthesis Design | 8 | 2015 | 161 | 0.330 |
Why?
|
| Health Services Research | 3 | 2013 | 261 | 0.320 |
Why?
|
| Biomechanical Phenomena | 7 | 2015 | 231 | 0.320 |
Why?
|
| Time Factors | 9 | 2015 | 3161 | 0.310 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 1945 | 0.310 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 838 | 0.310 |
Why?
|
| Fracture Healing | 3 | 2014 | 24 | 0.310 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 56 | 0.300 |
Why?
|
| Pain | 2 | 2022 | 317 | 0.290 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 4241 | 0.290 |
Why?
|
| Monitoring, Ambulatory | 1 | 2006 | 57 | 0.280 |
Why?
|
| Exercise Therapy | 1 | 2006 | 76 | 0.280 |
Why?
|
| Documentation | 1 | 2006 | 110 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 4 | 2015 | 147 | 0.280 |
Why?
|
| Elective Surgical Procedures | 2 | 2017 | 104 | 0.270 |
Why?
|
| Preoperative Period | 2 | 2016 | 57 | 0.270 |
Why?
|
| Adhesiveness | 1 | 2004 | 14 | 0.260 |
Why?
|
| Hydroxyapatites | 2 | 2014 | 5 | 0.250 |
Why?
|
| Polymethacrylic Acids | 2 | 2014 | 12 | 0.250 |
Why?
|
| Metals | 2 | 2018 | 60 | 0.250 |
Why?
|
| Patient Compliance | 1 | 2006 | 333 | 0.250 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2017 | 12 | 0.250 |
Why?
|
| Prevalence | 2 | 2022 | 1130 | 0.240 |
Why?
|
| Back Pain | 1 | 2023 | 38 | 0.230 |
Why?
|
| Bone Transplantation | 2 | 2014 | 23 | 0.230 |
Why?
|
| Rats | 9 | 2023 | 1675 | 0.230 |
Why?
|
| Stress, Mechanical | 5 | 2005 | 134 | 0.220 |
Why?
|
| Staphylococcus aureus | 2 | 2023 | 146 | 0.220 |
Why?
|
| Durapatite | 2 | 2015 | 24 | 0.220 |
Why?
|
| Recombinant Proteins | 7 | 2017 | 632 | 0.220 |
Why?
|
| Bone Regeneration | 2 | 2019 | 13 | 0.220 |
Why?
|
| Adult | 9 | 2015 | 13417 | 0.210 |
Why?
|
| Arthritis | 2 | 2021 | 42 | 0.210 |
Why?
|
| Cohort Studies | 3 | 2018 | 2123 | 0.200 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2019 | 54 | 0.200 |
Why?
|
| Ossification, Heterotopic | 3 | 1991 | 12 | 0.200 |
Why?
|
| Menisci, Tibial | 2 | 2017 | 13 | 0.190 |
Why?
|
| Cell Differentiation | 9 | 2017 | 1230 | 0.190 |
Why?
|
| Animals | 22 | 2023 | 17867 | 0.190 |
Why?
|
| Weight-Bearing | 4 | 2005 | 26 | 0.190 |
Why?
|
| Reoperation | 4 | 2012 | 177 | 0.180 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 108 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2017 | 95 | 0.180 |
Why?
|
| Osteoblasts | 3 | 2009 | 193 | 0.180 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 4 | 0.170 |
Why?
|
| Denmark | 1 | 2018 | 19 | 0.170 |
Why?
|
| Materials Testing | 4 | 2004 | 75 | 0.170 |
Why?
|
| Biofilms | 1 | 2019 | 55 | 0.170 |
Why?
|
| Workflow | 1 | 2018 | 50 | 0.170 |
Why?
|
| Physical Examination | 2 | 2016 | 95 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2018 | 115 | 0.160 |
Why?
|
| Surface Properties | 5 | 2014 | 251 | 0.160 |
Why?
|
| Tensile Strength | 3 | 2004 | 36 | 0.160 |
Why?
|
| Cadaver | 4 | 2005 | 92 | 0.160 |
Why?
|
| Radiography | 6 | 2009 | 373 | 0.150 |
Why?
|
| Musculoskeletal Pain | 1 | 2017 | 27 | 0.150 |
Why?
|
| Bone Marrow Cells | 4 | 2015 | 222 | 0.150 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 40 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2015 | 4746 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2009 | 151 | 0.150 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 77 | 0.150 |
Why?
|
| Aging | 3 | 2017 | 683 | 0.150 |
Why?
|
| Mice | 12 | 2023 | 9241 | 0.140 |
Why?
|
| Consensus | 1 | 2016 | 133 | 0.140 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1995 | 6 | 0.140 |
Why?
|
| Lactates | 1 | 2015 | 26 | 0.130 |
Why?
|
| Disease Management | 1 | 2016 | 177 | 0.130 |
Why?
|
| Cells, Cultured | 7 | 2016 | 1998 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2015 | 112 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 32 | 0.130 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2014 | 1 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2015 | 83 | 0.130 |
Why?
|
| Medical Audit | 1 | 2015 | 55 | 0.130 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2015 | 64 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 77 | 0.130 |
Why?
|
| Methacrylates | 1 | 2014 | 35 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 193 | 0.130 |
Why?
|
| Alloys | 4 | 2019 | 25 | 0.130 |
Why?
|
| Analysis of Variance | 3 | 2004 | 546 | 0.120 |
Why?
|
| Risk Factors | 4 | 2017 | 4352 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2013 | 23 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 161 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 1436 | 0.120 |
Why?
|
| Joint Diseases | 1 | 1993 | 17 | 0.120 |
Why?
|
| Hip Joint | 1 | 1993 | 28 | 0.120 |
Why?
|
| RANK Ligand | 2 | 2009 | 23 | 0.110 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2012 | 27 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 362 | 0.110 |
Why?
|
| Program Development | 1 | 2013 | 209 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2009 | 753 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 239 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2013 | 153 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2013 | 295 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 532 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 1993 | 169 | 0.110 |
Why?
|
| Apatites | 1 | 2011 | 2 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 492 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2015 | 729 | 0.100 |
Why?
|
| Logistic Models | 1 | 2015 | 1160 | 0.100 |
Why?
|
| Patient Dropouts | 1 | 2011 | 49 | 0.100 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 125 | 0.100 |
Why?
|
| Self Report | 1 | 2013 | 324 | 0.100 |
Why?
|
| Communication | 1 | 2015 | 475 | 0.100 |
Why?
|
| Cell Proliferation | 5 | 2017 | 894 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2013 | 156 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2015 | 486 | 0.100 |
Why?
|
| Data Collection | 1 | 2012 | 368 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2013 | 294 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2010 | 24 | 0.100 |
Why?
|
| Pyrazines | 1 | 2010 | 31 | 0.100 |
Why?
|
| Behavior Therapy | 1 | 2011 | 161 | 0.090 |
Why?
|
| Interleukin-1 | 1 | 2010 | 151 | 0.090 |
Why?
|
| Receptors, Leukotriene | 1 | 2009 | 3 | 0.090 |
Why?
|
| Leukotriene Antagonists | 1 | 2009 | 7 | 0.090 |
Why?
|
| Femur Head Necrosis | 1 | 2009 | 2 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2017 | 863 | 0.090 |
Why?
|
| Tetracycline | 1 | 2009 | 18 | 0.090 |
Why?
|
| Wnt Proteins | 2 | 2009 | 90 | 0.090 |
Why?
|
| Algorithms | 1 | 2015 | 897 | 0.090 |
Why?
|
| In Vitro Techniques | 4 | 2005 | 426 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 100 | 0.090 |
Why?
|
| Tibial Fractures | 1 | 2009 | 12 | 0.090 |
Why?
|
| Elastomers | 1 | 2009 | 7 | 0.090 |
Why?
|
| Bone Density | 3 | 2015 | 163 | 0.090 |
Why?
|
| Bone Remodeling | 1 | 2009 | 24 | 0.090 |
Why?
|
| Minerals | 1 | 2009 | 21 | 0.090 |
Why?
|
| Sterilization | 2 | 2001 | 14 | 0.090 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2009 | 32 | 0.090 |
Why?
|
| Decision Making | 1 | 2012 | 339 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1194 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2015 | 1596 | 0.090 |
Why?
|
| Awards and Prizes | 1 | 2008 | 26 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2009 | 135 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 464 | 0.080 |
Why?
|
| Calcium | 1 | 2011 | 518 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2008 | 144 | 0.080 |
Why?
|
| Equipment Failure Analysis | 2 | 2005 | 66 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 1779 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 452 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 125 | 0.080 |
Why?
|
| Compressive Strength | 3 | 2013 | 21 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 420 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2008 | 229 | 0.080 |
Why?
|
| Choristoma | 1 | 1986 | 21 | 0.080 |
Why?
|
| Cell Survival | 3 | 2015 | 521 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2006 | 37 | 0.070 |
Why?
|
| Osseointegration | 2 | 2014 | 5 | 0.070 |
Why?
|
| Polymethyl Methacrylate | 1 | 2004 | 13 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1467 | 0.060 |
Why?
|
| Carrier Proteins | 3 | 2010 | 659 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 181 | 0.060 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 10 | 0.060 |
Why?
|
| Micrococcal Nuclease | 1 | 2023 | 13 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 2908 | 0.060 |
Why?
|
| Collagen Type I | 2 | 2017 | 25 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 774 | 0.060 |
Why?
|
| Motor Activity | 1 | 2006 | 324 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2004 | 455 | 0.060 |
Why?
|
| Fractures, Stress | 1 | 2003 | 10 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2004 | 376 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 831 | 0.060 |
Why?
|
| Tissue Engineering | 2 | 2015 | 131 | 0.060 |
Why?
|
| Health Status | 1 | 2005 | 408 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2013 | 97 | 0.060 |
Why?
|
| Comorbidity | 1 | 2005 | 999 | 0.050 |
Why?
|
| Social Support | 1 | 2004 | 339 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1051 | 0.050 |
Why?
|
| Anxiety | 1 | 2004 | 343 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2009 | 2702 | 0.050 |
Why?
|
| Blood Loss, Surgical | 2 | 1997 | 39 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 1991 | 69 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2005 | 669 | 0.040 |
Why?
|
| Hypertrophy | 2 | 2009 | 24 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2008 | 1362 | 0.040 |
Why?
|
| Dalteparin | 1 | 1997 | 4 | 0.040 |
Why?
|
| Depression | 1 | 2004 | 765 | 0.040 |
Why?
|
| Premedication | 1 | 1997 | 17 | 0.040 |
Why?
|
| Thrombophlebitis | 1 | 1997 | 35 | 0.040 |
Why?
|
| Incidence | 1 | 2001 | 1128 | 0.040 |
Why?
|
| Periosteum | 1 | 2017 | 6 | 0.040 |
Why?
|
| Osteophyte | 1 | 2017 | 4 | 0.040 |
Why?
|
| Osteocalcin | 1 | 2017 | 46 | 0.040 |
Why?
|
| Rats, Inbred BB | 1 | 2017 | 76 | 0.040 |
Why?
|
| Switzerland | 1 | 2017 | 13 | 0.040 |
Why?
|
| Femur Neck | 1 | 1997 | 17 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 73 | 0.040 |
Why?
|
| Cell Line | 2 | 2013 | 1921 | 0.040 |
Why?
|
| Bone Plates | 1 | 1997 | 25 | 0.040 |
Why?
|
| Fracture Fixation, Internal | 1 | 1997 | 32 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 150 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2017 | 162 | 0.040 |
Why?
|
| Warfarin | 1 | 1997 | 98 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2017 | 69 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2017 | 49 | 0.040 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2016 | 3 | 0.040 |
Why?
|
| Knee Injuries | 1 | 2016 | 35 | 0.040 |
Why?
|
| Acetabulum | 1 | 2015 | 2 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 1997 | 245 | 0.030 |
Why?
|
| Postoperative Period | 1 | 1995 | 102 | 0.030 |
Why?
|
| Somatomedins | 1 | 1994 | 9 | 0.030 |
Why?
|
| Computer Simulation | 1 | 1997 | 428 | 0.030 |
Why?
|
| Torsion, Mechanical | 1 | 2014 | 4 | 0.030 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 37 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 14 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 22 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 285 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2014 | 9 | 0.030 |
Why?
|
| Macrophages | 2 | 2010 | 919 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 252 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 291 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 11 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 504 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2013 | 42 | 0.030 |
Why?
|
| Anticoagulants | 1 | 1997 | 424 | 0.030 |
Why?
|
| Elasticity | 1 | 2013 | 37 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1993 | 47 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 33 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 166 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2009 | 1886 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 99 | 0.030 |
Why?
|
| Amyloid | 1 | 1993 | 51 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2013 | 71 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1409 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2011 | 42 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 965 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 135 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 35 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 44 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2011 | 187 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 54 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 70 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 164 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2009 | 12 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 178 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 140 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2009 | 23 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2009 | 10 | 0.020 |
Why?
|
| Myoblasts, Skeletal | 1 | 2009 | 12 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 139 | 0.020 |
Why?
|
| Sulfides | 1 | 2009 | 16 | 0.020 |
Why?
|
| Acetates | 1 | 2009 | 25 | 0.020 |
Why?
|
| Bony Callus | 1 | 2009 | 3 | 0.020 |
Why?
|
| Quinolines | 1 | 2009 | 33 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2009 | 33 | 0.020 |
Why?
|
| Freeze Drying | 1 | 2009 | 12 | 0.020 |
Why?
|
| Powders | 1 | 2009 | 17 | 0.020 |
Why?
|
| Cartilage | 1 | 2009 | 27 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2009 | 53 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 277 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 488 | 0.020 |
Why?
|
| Risk | 2 | 1987 | 358 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 62 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 34 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2010 | 233 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 616 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 18 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 1076 | 0.020 |
Why?
|
| Steel | 1 | 2008 | 1 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 102 | 0.020 |
Why?
|
| Chromium | 1 | 2008 | 5 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 121 | 0.020 |
Why?
|
| Cobalt | 1 | 2008 | 17 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 244 | 0.020 |
Why?
|
| Water | 1 | 2009 | 270 | 0.020 |
Why?
|
| Hip | 1 | 1987 | 8 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1986 | 103 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 11 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2006 | 8 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2006 | 4 | 0.020 |
Why?
|
| Growth Plate | 1 | 2006 | 13 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2006 | 19 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1257 | 0.020 |
Why?
|
| beta Catenin | 1 | 2006 | 85 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1986 | 101 | 0.020 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2006 | 139 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 522 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2006 | 110 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 707 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2006 | 535 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 485 | 0.020 |
Why?
|
| Pressure | 1 | 2005 | 64 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 823 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2006 | 342 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2006 | 283 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 796 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 1097 | 0.020 |
Why?
|
| Biomarkers | 1 | 2008 | 999 | 0.020 |
Why?
|
| Motion | 1 | 2003 | 49 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 646 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 303 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 597 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 372 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1314 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 1369 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1997 | 240 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1994 | 8 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1994 | 24 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1994 | 73 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1994 | 39 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 53 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1994 | 177 | 0.010 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1994 | 24 | 0.010 |
Why?
|
| Absorptiometry, Photon | 1 | 1994 | 86 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 173 | 0.010 |
Why?
|
| Rabbits | 1 | 1994 | 300 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 390 | 0.010 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 1987 | 1 | 0.000 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1987 | 22 | 0.000 |
Why?
|